.Pharmacolibrary.Drugs.S_SensoryOrgans.S01E_AntiglaucomaPreparationsAndMiotics.S01EE04_Travoprost.Travoprost .Pharmacolibrary.Drugs.S_SensoryOrgans.S01E_AntiglaucomaPreparationsAndMiotics.S01EE04_Travoprost.Travoprost| name: | Travoprost | |
| ATC code: | S01EE04 | route: | ophthalmic |
| compartments: | 1 | |
| dosage: | 0.04 | mg |
| volume of distribution: | 56 | L |
| clearance: | 42.5 | L/hr |
| other parameters in model implementation | ||
Travoprost is a prostaglandin analog used for the reduction of elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension. It is administered as an ophthalmic solution and is approved and widely used for ocular hypertension and glaucoma management.
Pharmacokinetic parameters are reported in healthy adult volunteers following ocular administration.
DuBiner, HB, & Hubatsch, DA (2014). Late-day intraocular pressure-lowering efficacy and tolerability of travoprost 0.004% versus bimatoprost 0.01% in patients with open-angle glaucoma or ocular hypertension: a randomized trial. BMC ophthalmology 14 151–None. DOI:10.1186/1471-2415-14-151 PUBMED:https://pubmed.ncbi.nlm.nih.gov/25432143
Hariharan, S, et al., & Mitra, AK (2009). Interaction of ocular hypotensive agents (PGF2 alpha analogs-bimatoprost, latanoprost, and travoprost) with MDR efflux pumps on the rabbit cornea. Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics 25(6) 487–498. DOI:10.1089/jop.2009.0049 PUBMED:https://pubmed.ncbi.nlm.nih.gov/20028257